miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
about
Clinical significance of microRNAs in chronic and acute human leukemiaTherapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsDetection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.FBXL20-mediated Vps34 ubiquitination as a p53 controlled checkpoint in regulating autophagy and receptor degradation.Roles of F-box proteins in cancerPrognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaHigh expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.Mitogen-activated protein kinase binding protein 1 (MAPKBP1) is an unfavorable prognostic biomarker in cytogenetically normal acute myeloid leukemia.The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemiaThe expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.miRNAs in acute myeloid leukemia.Acute myeloid leukemia with normal cytogenetics.MicroRNAs in myeloid malignancies.Hematological malignancies: role of miRNAs and their in silico aspects.Noncoding RNAs in Acute Myeloid Leukemia: From Key Regulators to Clinical PlayersPrognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?MicroRNA regulation of F-box proteins and its role in cancer.Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome.Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis.Recent advances in SCF ubiquitin ligase complex: Clinical implicationsLet-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia.Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
P2860
Q26749533-908D5835-E7AA-4DD7-BCBC-8D758B302229Q28071427-0E7D27B2-06C7-4B78-9F39-F40A898E2179Q33999386-D049D803-78BE-4C15-BF6C-F9DF2E8DB043Q34193684-0CBB6005-9F0F-4EAC-BBC7-0E50F0F98B66Q34831106-74FE9090-5F79-47D3-A1C7-098F64ED0DA5Q34981648-C43849BF-6F2E-4693-A6A6-6553594BFF38Q35012352-DC08B828-D516-47CA-A909-259F62D90E0AQ35152173-008B933A-A52E-46E7-8BDB-BB3754E5A3FEQ35741669-E17857C0-BE62-4AC9-A572-E8754BDEB27DQ35781530-A743F9D7-A918-4376-AE3A-BCE6E3B96DDAQ35853830-A0F898A9-FBEE-4E11-A59A-DA35EAB4C200Q36254225-484935AB-9AEF-45E4-8F73-E9082035D059Q36688994-79B31A5A-48D0-4A2F-B2C3-31928FAE276EQ36891005-3B7DDB26-7750-4B75-B6A1-BB9B0493EB4FQ37474559-881560E0-87EF-42E6-B112-ED4F19C9830BQ37644854-0D6FBF42-F73A-4BBF-A1DF-D5E5CB605EECQ37709531-762C8295-8231-4A2E-89F3-E89864F5D2ADQ38027047-E1A6C4A7-E3DE-45C5-B560-461CA05313FAQ38107272-BA239A94-1B83-4FD4-9ADF-ACA5F23BDF2FQ38140001-2240BB19-D943-453A-AB7A-A267BACAF5D2Q38166375-357B250F-8773-4635-80F5-524B2885F311Q38183943-084B3C05-5797-436E-B2C6-52353F57DECDQ38199056-9538ADE5-3256-4B4B-B9A5-51CE6734C786Q38577492-846EC022-7815-4072-B641-126D25AEF9A3Q38693627-0D2CBD96-A1BD-4CE6-8DF2-9FBF44427122Q38821561-AEB002DB-72D4-4D3B-A185-9EAAED94A5A4Q38828721-104EFE05-10B8-436C-BA8C-0A9AE5E095F1Q38847748-69A255BC-B299-4F74-89E3-A4D7C616F3CFQ39181050-5C027B2E-CA84-4149-886C-94F3945FAC0AQ40862157-1404FB46-A744-4BFF-8DF5-9B2CA6AF7216Q43850689-B0E7184F-DE0C-46E9-AC0F-E08695649CC2Q50913559-F7CA29E9-2CB0-4FA7-AC38-BD3BE5E0D74E
P2860
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@ast
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@en
type
label
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@ast
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@en
prefLabel
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@ast
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@en
P2093
P2860
P50
P1433
P1476
miR-3151 interplays with its h ...... normal acute myeloid leukemia
@en
P2093
Ann-Kathrin Eisfeld
Bayard L Powell
Deedra Nicolet
Heiko Becker
Jonathan E Kolitz
Joseph O Moore
Maria R Baer
Meir Wetzler
Michael A Caligiuri
Michael D Radmacher
P2860
P304
P356
10.1182/BLOOD-2012-02-408492
P407
P50
P577
2012-04-23T00:00:00Z